Publish
Home
Live
new
RH Journal
ResearchCoin
Grants
Funding
Browse
Journals
Hubs
Tools
Lab Notebook
Beta
Reference Manager
Resources
Verify Identity
Community
Support
About
Terms
Privacy
Issues
Docs
Author
Log in
Sign up
AI
Antonia Izquierdo
Author with expertise in Lymphoid Neoplasms
Achievements
This user has not unlocked any achievements yet.
Key Stats
Upvotes received:
0
Publications:
5
(0% Open Access)
Cited by:
0
h-index:
6
/
i10-index:
5
Reputation
Biology
< 1%
Chemistry
< 1%
Economics
< 1%
Show more
How is this calculated?
Overview
Publications
5
Peer Reviews
Comments
Grants
Publications
0
Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response
Alejandro Martín-Muñoz
et al.
Nov 5, 2024
Oncology
Internal Medicine
0
Paper
Oncology
Internal Medicine
0
Save
0
Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma
Ana Jiménez‐Ubieto
et al.
Nov 5, 2024
Genetics
Oncology
0
Paper
Genetics
Oncology
0
Save
0
Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331
Ramón García‐Sánz
et al.
Nov 5, 2024
Oncology
Internal Medicine
0
Paper
Oncology
Internal Medicine
0
Save
0
PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
Tae Kim
et al.
Nov 5, 2024
Biochemistry
Oncology
0
Paper
Biochemistry
Oncology
0
Save
0
The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)
Anna Balarí
et al.
Nov 5, 2024
Oncology
Internal Medicine
0
Paper
Oncology
Internal Medicine
0
Save